NeuroMetrix said on Tuesday that it initiated a process to review strategic options to grow its neuromodulation and neurodiagnostic businesses. The Woburn, Massachusetts-based company wants to promote the growth of its Quell and DPNCheck offerings and maximize shareholder value. It said it plans to consider a wide range of options. That could include marketing strategies, […]
Neurometrix
NeuroMetrix is expanding its salesforce
NeuroMetrix (Nasdaq: NURO) second-quarter results took a hit from challenges related to reimbursement changes at CMS, but Quell Fibromyalgia saw positive trends. The Woburn, Massachusetts–based company’s Quell neuromodulation device won FDA de novo nod to treat fibromyalgia in May 2022. The company had 123 unique prescribers for the fibromyalgia therapy in Q2, versus 92 in […]
NeuroMetrix launches peripheral neuropathy test
NeuroMetrix (Nasdaq:NURO) announced today that it commercially launched its DPNCheck 2.0 point-of-care device. Woburn, Massachusetts–based NeuroMetrix designed DPNCheck 2.0 to use nerve conduction technology to detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient screening with quantitative measurement of peripheral nerve function. It features an easy-to-use touchscreen, step-by-step onboarding instructions and improved temperature compensation. Additionally, it […]
NeuroMetrix strategically launches Quell Fibromyalgia
NeuroMetrix (Nasdaq: NURO) announced the strategic launch of its Quell Fibromyalgia device through its Pathfinder Program. The move — announced yesterday — comes nearly 6 months after NeuroMetrix said it had received an FDA de novo authorization to use its Quell neuromodulation device to treat fibromyalgia symptoms. The Pathfinder Program starts Dec. 1. NeuroMetrix limited […]
NeuroMetrix’s Quell neuromodulation device wins FDA de novo nod to treat fibromyalgia
NeuroMetrix (Nasdaq:NURO) announced today that it received FDA de novo authorization for its Quell neuromodulation device. Quell received the authorization as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. Quell garnered FDA breakthrough device designation to treat fibromyalgia in July 2021. Much like when it received the breakthrough nod, […]
NeuroMetrix revenues rise in Q1
NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]
NeuroMetrix reports Q4 losses
NeuroMetrix (NSDQ:NURO) today reported fourth-quarter results that included a bottom-line slide. The Woburn, Massachusetts–based neurostimulation technology developer posted losses of $1 million, or 15¢ per share, on sales of $1.8 million for the three months ended Dec. 31, 2021, for a bottom-line dip deeper into the red on sales growth of 0.6%. NeuroMetrix develops the […]
NeuroMetrix’s Quell wins FDA breakthrough designation to treat certain chemo side effects
NeuroMetrix (NSDQ:NURO) announced today that it received FDA breakthrough device designation for its Quell technology. Woburn, Massachusetts-based NeuroMetrix’s Quell garnered the breakthrough nod for reducing moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least six months following the end of chemotherapy. Shares of NURO were up 36.6% at $6.72 per share […]
NeuroMetrix rises on Q3 results, projects Quell launch in 2022
NeuroMetrix (NSDQ:NURO) shares are on the rise today after the company released third-quarter financial results last week. NURO shares were up 7.9% at $7.92 per share in mid-morning trading. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.2%. The Woburn, Massachusetts-based company posted losses of […]
NeuroMetrix stock slides on publication of Quell study
NeuroMetrix (NSDQ:NURO) stock is hitting a massive skid this week after the publication of a study on its Quell non-invasive nerve stimulation device for pain relief. Shares of NURO were down -12.2% at $18.41 apiece by late-afternoon trading yesterday on the news. The stock continues to decline today, down –7.1% to $16.94 per share by […]
MedTech 100 roundup: Return to normal after last week’s spike
After rising more than 31 points to heights never before reached, the medtech industry returned to normal this past week. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (July 23) at 115.54 points, a total that, had it not been for the previous week, would […]
